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ABSTRACT 
Background: We examined whether abnormal skeletal muscle Na+,K+-pumps underlie impaired 
exercise performance in haemodialysis patients (HDP), and whether these are improved in renal 
transplant recipients (RTx).  
Methods: Peak oxygen consumption ( V
•
O2peak) and plasma [K+] were measured during incremental 
exercise in 9 RTx, 10 HDP, and 10 healthy controls (CON). Quadriceps peak torque, fatigability 
(decline in strength during thirty contractions), thigh muscle cross-sectional area (TMCSA) and 
vastus lateralis Na+,K+-pump maximal activity, content, and isoform (α1-α3, β1-β3) abundance were 
measured. Results: V
•
O2peak was 32% and 35% lower in RTx and HDP than CON, respectively 
(P<0.05). Peak torque was less in RTx and HDP than CON (P<0.05) but did not differ when 
expressed relative to TMCSA. Fatigability was ~1.6-fold higher in RTx (24±11%) and HDP 
(25±4%) than CON (15±5%), P<0.05). Na+,K+-pump activity was 28% and 31% lower in RTx and 
HDP, respectively than CON (P<0.02), whereas content and isoform abundance did not differ. 
Pooled (n=28) V
•
O2peak correlated with Na+,K+-pump activity (r=0.45, P=0.02).  
Conclusions: V
•
O2peak and muscle Na+,K+-pump activity were depressed and muscle fatigability 
increased in HDP, with no difference observed in RTx. These findings are consistent with the 
possibility that impaired exercise performance in HDP and RTx may be partially due to depressed 
muscle Na+,K+-pump activity and relative TMCSA. 
 
Keywords: extrarenal potassium regulation, fatigue, muscle mass, strength, V
•
O2peak 
Summary 
We show that peak oxygen consumption, quadriceps strength and fatigability are not different 
between haemodialysis patients (HDP) and renal transplant recipients (RTx) with similar 
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[ Hb] , however they are reduced in both groups compared to matched healthy control 
subjects (CON). Skeletal muscle maximal Na+ ,K+ -pump activity was depressed in HDP and 
RTx compared to CON, whereas skeletal muscle Na+ ,K+ -pump content and isoform 
abundance did not differ. When all results were pooled, peak oxygen consumption correlated 
with Na+ ,K+ -pump activity, suggesting that impaired exercise performance in HDP and RTx 
may be partially due to depressed muscle Na+ ,K+ -pump activity.
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INTRODUCTION 
Patients with chronic kidney disease have grossly impaired exercise tolerance [1], but differences in 
exercise capacity between haemodialysis patients (HDP) and renal transplantation recipients (RTx) 
are poorly defined. Following renal transplantation, the V
•
O2peak of previously anaemic HDP has 
been reported to increase by 25–38% [2, 3]. Post-transplantation increases in haemoglobin 
concentration ([Hb]) and haematocrit (Hct) may account for much of the improvement, as increases 
in V
•
O2peak of 19-33% have been reported in HDP following treatment with erythropoietic 
stimulating agents (ESA) [4, 5]. Nonetheless, no studies have investigated V
•
O2peak in RTx and HDP 
with similar [Hb] to properly compare these groups. 
Muscle strength and fatigability are important determinants of exercise capacity [6, 7]. Muscle 
strength is impaired in non ESA-treated HDP [8], likely due to reduced muscle mass [9], and is 
unlikely to improve with ESA treatment [10]. However, RTx does not improve muscle strength [8, 
11], possibly due to the muscle wasting effects of glucocorticoid therapy [12].  Muscle fatigability 
during repeated maximal isometric hand-grip contractions was greater, and Hct lower in non ESA-
treated HDP than RTx [13]. No studies have examined fatigability during dynamic contractions in 
RTx, or between RTx and ESA-treated HDP with similar [Hb].  
If exercise performance remains impaired in RTx, an underlying muscle defect may persist, 
contributing to greater fatigability. A possible mechanism of fatigue is impaired muscle membrane 
excitability, caused by elevated interstitial [K+] [14], which is likely exacerbated in HDP. Anaemic 
HDP exhibited pronounced hyperkalaemia during exercise, which was inversely correlated with V
•
O2peak [15]. A reduced muscle compound action potential in HDP [16] suggests impaired membrane 
excitability. Hence, abnormal K+ regulation might enhance fatigue and reduce exercise 
performance. We tested the hypothesis that regulation of plasma [K+] during incremental exercise 
would be impaired in both HDP and RTx.  
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Skeletal muscle contains the largest pool of Na+,K+-pumps [17], and is vital in extrarenal K+ 
regulation [18]. Reduced Na+,K+-pump activity was found in muscle from uremic rats [19] despite 
normal content and isoform abundance [19, 20], suggesting an underlying defect in existing pumps. 
Thus, impaired muscle Na+,K+-pump activity could underlie the abnormal plasma K+ responses in 
HDP [15]. Possible abnormalities in skeletal muscle Na+,K+-pump activity, content or isoform 
abundance, have not been investigated in uremic humans. Erythrocytic Na+,K+-pump activity was 
improved following renal transplantation [21], but whether skeletal muscle Na+,K+-pump activity in 
RTx is impaired is not known.  
This study tested the hypothesis that V
•
O2peak, muscular strength and fatigability would be worsened 
compared to CON, but would not be different between RTx and ESA-treated HDP with similar 
[Hb]. We also tested the hypotheses that muscle Na+,K+-pump activity would be depressed in both 
HDP and RTx, with normal Na+,K+-pump content and isoform abundance. Finally we explored 
whether depressed muscle Na+,K+-pump activity in HDP and RTx would be related to their poor K+ 
regulation and exercise performance. 
METHODS 
Subjects 
Nine RTx, ten HDP, and ten CON gave written informed consent and participated in the study. One 
HDP underwent all tests except the muscle biopsy. Subjects were matched for sex, age, height, 
bodymass and bodymass index (BMI) (Table 1). Selection criteria for RTx were: transplanted at 
least 12 mo prior to testing (range 16–171, 63±53 mo), had a stable creatinine, and a calculated 
CrCl (Cockcroft-Gault) of >40 ml.min-1. Selection criteria for HDP were: stable and had been 
dialyzing for at least 6 mo (range 7–71, 38±23). All HDP were anuric and urea reduction ratio was 
65±5%. Ultrafiltration rate was 0.4-0.7 l.h-1 according to patient size, intradialytic time, and pre-
dialysis weight. All subjects had [Hb] >110 g.l-1. Subjects were excluded if they had symptomatic 
ischemic heart disease, peripheral vascular disease, disabling arthritis, chronic airflow obstruction, 
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or were pregnant. Subject medications are shown in Table 3. The RTx received kidneys from living 
related donors (n=2), living non-related donors (n=2), and from deceased donors (n=5). This study 
was approved by the Human Research Ethics Committees at Victoria University and Melbourne 
Health. 
Exercise tests 
For HDP, all exercise tests were performed on a non-dialysis day with a mean time of 31±14 h) post 
dialysis.  
Peak oxygen consumption ( V
•
O2peak): Subjects cycled (≥60 rpm) on an electronically braked cycle 
ergometer (Lode, Groningen, Holland), with increments of 15 W each minute until volitional 
exhaustion [22], with expired gases and ventilation continuously measured to calculate V
•
O2 [23].  
Quadriceps torque-velocity test: Subjects performed three maximal isokinetic contractions at 0, 60, 
120, 180, 240, 300, and 360°.s-1, with 60 s recovery between sets, on an isokinetic dynamometer 
(Cybex Norm-770, Henley HealthCare, Massachusetts) [24]. The highest value of each set of three 
was defined as the peak torque (PT) and expressed relative to body mass (Nm.kg-1) and TMCSA 
(Nm.cm-2), to correct for differences in body size and muscle mass, respectively.  
Quadriceps fatigue test: Subjects performed 30 maximal isokinetic contractions at 180°.s-1, with ~1 
s pause between repetitions [24]. The fatigue index (FI,%) was calculated as [(starting PT - final 
PT)/ starting PT] x 100, where starting PT is the average of the highest three of the first five 
repetitions; final PT is the average of the highest three of the last five repetitions. 
Blood sampling and processing 
Blood was sampled before, during and after the V
•
O2peak test from an arterio-venous fistula in all 
HDP, and in four RTx; in all other subjects, arterialised venous blood was sampled from a heated 
dorsal hand-vein [25]. The different blood sampling sites used are unlikely to have impacted on 
[K+], since arterialised venous [K+] did not differ from arterial [K+] during low-to-moderate 
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intensity exercise, and was only marginally higher (4%) during high intensity exercise [26]. Blood 
was analysed in duplicate for [Hb] and Hct (Sysmex, K-800, Kobe, Japan) and for plasma [K+] 
(865pH/Blood Electrolyte and Gas Analyzer, Bayer, MA, USA). ΔPV was calculated [27] and used 
to correct [K+] for fluid shifts [28]. Additional calculations were ∆[K+] and ∆[K+].work-1 ratio [28-
30]. Possible medication effects on plasma [K+] were considered. Whilst non-selective β-blockers 
increase plasma [K+] during exercise [31], only β1-blockers were taken by subjects in this study, 
which do not affect [K+] during exercise [32]. Prednisone increases skeletal muscle Na+,K+-pump 
content [33], which could lower plasma [K+] during exercise. However, in the present study, plasma 
[K+] during exercise was not different within groups between the patients taking prednisone and 
those who were not (data not shown). 
Computerised Tomography scan 
TMCSA of the dominant leg was measured by single slice Computerised Tomography (CT) scan, 
taken 20 cm above the medial femoral condyle. Muscle area was calculated as the total muscle 
compartment area minus the femur area [24]. 
Muscle biopsy 
Prior to the torque-velocity and fatigue tests, a muscle sample was collected from the vastus 
lateralis under local anaesthesia (1% Xylocaine) by percutaneous needle biopsy technique.  
Muscle Na+,K+-pump analyses 
Maximal activity and total content: The maximal in-vitro Na+,K+-pump activity was measured in 
muscle homogenates using the maximal K+-stimulated 3-O-methylfluorescein phosphatase 
(3-O-MFPase) assay, specific for the Na+,K+-pump and adapted for human skeletal muscle [25, 34]. 
Total Na+,K+-pump content was determined by vanadate-facilitated [3H]ouabain binding site 
content analysis [25, 35]. 
Isoform abundance: Western blotting was performed for the α1, α2, α3, β1, β2, and β3 Na+,K+-pump 
isoforms as detailed [36], with the modification that the muscle homogenate was deglycosylated 
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prior to electrophoresis, to enhance β-isoform identification. This involved incubating the 
homogenate for 1 h at 37°C with 0.5% (v/v) Nonidet P40 and 3 units N-Glycosidase F (Boehringer 
Mannheim) per 0.5 mg protein. The final blot intensity was normalised to the same human muscle 
standard which was run in all gels.  
Antibodies: Antibodies specific to each isoform were for α1: monoclonal α6F (developed by D. 
Fambrough and obtained from the Developmental Studies Hybridoma Bank developed under the 
auspices of the NICHD and maintained by the University of Iowa, Department of Biological 
Sciences, Iowa City, IA); α2: polyclonal anti-HERED (kindly donated by T. Pressley, Texas Tech 
University); α3: monoclonal MA3-915 (Affinity Bioreagents, Golden, Colorado); β1:  monoclonal 
MA3-930 (Affinity Bioreagents); β2: monoclonal 610915 (Transduction Laboratories, Lexington, 
Kentucky); and β3: monoclonal 610993 (Transduction Laboratories).  
Statistics 
Data are mean ± SD. A one-way ANOVA was used except when repeated measures were taken 
(e.g. [K+] data) for which a mixed-design two-way ANOVA was used. The Least Significant 
Difference post-hoc test was used because of the unequal group sizes. Correlations were determined 
by linear regression. Significance was accepted at P<0.05. 
RESULTS 
Physical characteristics 
Physical characteristics did not differ between groups (Table 1) except lower TMCSA expressed 
relative to bodymass in RTx (P=0.017) and HDP (P=0.006) than in CON. Calculated CrCl was also 
lower in RTx (P=0.001) than CON. When data from all groups were pooled, relative TMCSA was 
correlated with estimated CrCl (r=0.44, P=0.026, n=28). 
Exercise performance  
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Quadriceps torque-velocity: PT (Nm.kg-1) was ~25% lower in RTx and HDP than CON (P<0.05) at 
all velocities except 120°.s-1, where only RTx was lower (Fig.1). However, PT (Nm.cm-2) did not 
differ between groups (Fig.1).  
Quadriceps fatigue: The FI was higher in RTx (24%, P=0.010) and HDP (25%, P=0.003) than in 
CON (15%), with no difference between RTx and HDP.  
Peak oxygen consumption: V
•
O2peak was less in RTx (27.0±9.6 ml.kg-1.min-1, P=0.012) and HDP 
(26.4±6.5 ml.kg-1.min-1, P=0.006), respectively than CON (35.7±4.0 ml.kg-1.min-1), with no 
difference between RTx and HDP. Peak workrate similarly was lower by 29 and 31%, respectively 
in RTx (P=0.005) and HDP (P=0.003) than CON (Fig.2). Total work done was also lower in RTx 
(60.6 ±41, P=0.009) and HDP (56.8±23, P=0.004) than CON (114.8±54 kJ). RER at V
•
O2peak was 
not different between groups (RTx 1.17±0.08, HD 1.25±0.10, and CON 1.19±0.06. For pooled data, 
V
•
O2peak was correlated with TMCSA (Fig. 5), relative TMCSA (r=0.72, P=0.001, n=28) and PT 
(r=0.83, P=0.001, n=29) and inversely correlated with FI (r=-0.53, P=0.004, n=29). TMCSA was 
correlated with PT (r=0.75, P=0.001, n=28) but not FI. 
Plasma [K+] and fluid shifts 
The change in plasma volume from rest (ΔPV), during incremental exercise to peak workrate was 
less in RTx (-12.7±2.5) than in both HDP (-15.8±2.9, P=0.032) and CON (-16.2±3.1%, P=0.014). 
Therefore, plasma [K+] was corrected for the ΔPV. Corrected plasma [K+] was higher (P<0.05) in 
HDP than in RTx and CON at rest, during exercise and at 10 min post-exercise (Fig.2). The rise in 
plasma [K+] above rest (∆[K+]) did not differ between groups during common submaximal 
workrates, but was less in RTx (P=0.014) and HDP (P=0.004) at peak workrate compared to CON 
(Fig.2). To correct for the greater peak workrate in CON, Δ[K+] was expressed relative to the total 
work done (Δ[K+].work-1 ratio). No difference was found between the groups in Δ[K+].work-1 ratio 
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(RTx 20.8±15.6, HDP 14.9±8.5, CON 15.6±10.4 nmol.l-1.J-1). When data were pooled, V
•
O2peak was 
inversely correlated with the Δ[K+].work-1 ratio (r=-0.42, P=0.030, n=29). 
Muscle Na+,K+-pump activity, content and isoforms 
Total muscle protein content: Muscle protein content did not differ between groups (RTx 
0.18±0.02, HDP 0.17±0.03, CON 0.19±0.03 mg protein.mg muscle (wet weight)-1). 
Maximal activity and content: Muscle maximal 3-O-MFPase activity was 28% and 31% lower in 
RTx (P=0.020) and HDP (P=0.010) than CON, respectively (Fig.3). In contrast, the [3H]ouabain 
binding site content did not differ between the groups (Fig.3). Within HDP, 3-O-MFPase activity 
was positively correlated with V
•
O2peak (r=0.73, P<0.05, n=9) and isometric PT (r=0.84, P<0.0 5, 
n=9). No significant correlations were found within RTx or CON between 3-O-MFPase activity and 
any exercise performance variables. For pooled data, 3-O-MFPase activity correlated with V
•
O2peak 
(Fig.4) and [3H]ouabain binding site content (r=0.42, P=0.026, n=28).  
Isoform abundance: Each of the Na+,K+-pump α1, α2, α3, β1, β2, and β3 isoforms were expressed in 
muscle from all HDP and RTx patients and CON. There was no significant difference between 
groups in protein abundance for any Na+,K+-pump isoform (Table 2). 
 
DISCUSSION 
This study identifies two possible mechanisms underlying impaired muscle function and exercise 
performance in renal transplantation recipients and haemodialysis patients, namely reduced skeletal 
muscle Na+,K+-pump activity and reduced TMCSA relative to bodymass. Furthermore, both 
Na+,K+-pump maximal activity and relative TMCSA, as well as muscle fatigability and exercise 
performance did not differ between RTx and HDP with normal [Hb]. Significant inter-relationships 
further strengthen the possibility that the impaired exercise performance in RTx and HDP may be 
linked to reduced Na+,K+-pump maximal activity and relative TMCSA. 
Reduced maximal Na+,K+-pump activity but not abundance 
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This is the first study to measure skeletal muscle Na+,K+-pump activity, content or isoforms in 
uraemic patients. Muscle maximal Na+,K+-pump activity was reduced by ~30% in RTx and HDP. 
This is consistent with reports in uraemic patients of reduced Na+,K+-pump activity in other tissues 
[37, 38], reduced muscle intracellular [K+] [39], muscle membrane depolarization [40], and 
impaired muscle membrane excitability [16]. Surprisingly, there was no difference in maximal 3-O-
MFPase activity between RTx and HDP. We hypothesized that Na+,K+-pump activity would be 
normal in RTx, based on findings in erythrocytes of normal or elevated Na+,K+-pump activity after 
RTx in many [21, 41, 42] although not all studies [43].  
We confirmed the expression of the Na+,K+-pump α1, α2, α3, β1, β2, and β3 isoforms [36] in muscle 
from RTx and HDP, and demonstrate an unchanged relative isoform abundance compared to CON. 
These results support the findings of unchanged Na+,K+-pump isoform mRNA expression or protein 
abundance in skeletal muscle of nephrectomized and sham-operated rats [20]. There was a non-
significant ~2-fold difference between HDP and CON in the relative abundance of the α1 and α3 
isoforms. Thus, we cannot exclude the possibility that some differences in isoform expression exist 
but that these were not detectable due to the intrinsic variability of Western blotting. However, 
failure to detect significant differences between groups for isoform abundance was unlikely due to 
the small sample size as effect sizes were very small (range 0.03–0.15).  
Possible mechanisms of impaired maximal Na+,K+-pump activity 
As muscle Na+,K+-pump content and isoform expression were not reduced in RTx and HDP, their 
depressed Na+,K+-pump activity appears to be due to defective Na+,K+-pump function. We show 
that Na+,K+-pump content is normal in uraemic human skeletal muscle, consistent with findings in 
uraemic rats [19]. The lower activity in HDP and RTx did not abolish the previously described 
positive association between maximal 3-O-MFPase activity and [3H]ouabain binding site content 
[30]. As the HDP were hyperkalaemic, which increases Na+,K+-pump content in rat muscle [44], 
possible hyperkalaemic effects on Na+,K+-pump content and activity cannot be excluded. 
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Normal muscle Na+,K+-pump content in these patients suggests that their depressed maximal 
Na+,K+-pump activity is due to reduced molecular activity per pump, or grossly impaired activity in 
some pumps. This is consistent with a previous finding in erythrocytes from HDP of reduced 
ouabain-sensitive 86Rb+ uptake but normal [3H]ouabain binding site content [45]. We cannot 
compare the molecular activities with previous reports, which were calculated using different 3-O-
MFPase assay conditions [46]. With numerous myopathies identified in RTx and HDP, the cause of 
reduced Na+,K+-pump activity is likely to be multi-factorial. Changes in membrane lipid 
composition can alter Na+,K+-pump activity without altering Na+,K+-pump content [47] and 
abnormal membrane lipid composition has been found in erythrocytes from HDP [37] and RTx 
[48], as well as in kidney, liver and testis microsomal membranes from rats following renal 
transplantation [49]. In uraemia, endogenous digitalis-like factors [37] and uraemic toxins [50] in 
plasma can depress Na+,K+-pump activity. In RTx, calcineurin inhibitors reduce Na+,K+-pump 
activity in heart [51] and kidney [52]. Conversely, prednisolone, increases muscle Na+,K+-pump 
content [33] and possibly also activity [53]. Further research is required to determine the 
mechanisms inhibiting Na+,K+-pump activity in skeletal muscle in RTx and HDP. 
Reduced relative TMCSA and impaired exercise performance in HDP and RTx with normal [Hb] 
This is the first report demonstrating exacerbated muscle fatigability during repeated dynamic 
contractions in RTx compared to CON. Further, we show similar fatigability between RTx and 
HDP. This contrasts findings of greater fatigability in HDP than RTx during repeated isometric 
hand-grip contractions [13], possibly due to a lower Hct in HDP in that study.  
This is the first study comparing V
•
O2peak in RTx and HDP with similar [Hb], revealing that V
•
O2peak 
did not differ between RTx and HDP, but was ~25% less than CON. This confirms the poor 
exercise performance in RTx and HDP, which persists despite normalisation of [Hb] [5, 54] and is 
consistent with greater muscle fatigability. In addition, we found an apparent relationship between 
maximal exercise performance ( V
•
O2peak) and, muscle Na+,K+-pump maximal activity (3-O-MFPase 
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activity). This is consistent with the possibility that impaired exercise performance in RTx and HDP 
may be related to reduced muscle function associated with lower Na+,K+-pump activity. Since the 
Na+,K+-pump protects muscle membrane excitability and delays fatigue [14, 18], depressed 
maximal Na+,K+-pump activity in HDP and RTx may impair exercise performance and V
•
O2peak. It 
should be noted that Na+,K+-pump maximal activity explained 20% of the variance in V
•
O2peak, and 
thus other factors must also contribute to their poor exercise performance, including  limb muscle 
atrophy [9], altered muscle fibre type [55], impaired blood flow [56], reduced muscle capillarity 
[56] and mitochondrial function[9].  
Quadriceps strength was subnormal in RTx and HDP when corrected for bodymass but not when 
expressed relative to TMCSA. This suggests that muscle contractile function is normal in RTx and 
HDP with normal [Hb] and that their strength deficit may be entirely due to reduced lean bodymass 
[57]. This is an important finding as it indicates that strategies to improve physical functioning in 
HDP and RTx should focus on increasing muscle mass. It is also consistent with our finding of 
reduced TMCSA relative to bodymass in RTx and HDP. We also report no difference in quadriceps 
strength in RTx compared to HDP, which supports previous studies [8, 11]. Not surprisingly, V
•
O2peak was correlated with relative TMCSA and peak torque. This is the first report of a relationship 
between muscle strength and V
•
O2peak in RTx. We also found an inverse relationship between V
•
O2peak and the FI. These data, together with a lack of correlation between V
•
O2peak and [Hb], support 
the concept that reduced muscle mass plays a vital role in limiting V
•
O2peak and strength in RTx and 
HDP. 
Normal plasma K+ regulation during exercise in HDP and RTx 
Our finding of normal Δ[K+] during exercise and Δ[K+].work-1 ratio at peak workrate in RTx and 
HDP contrasts with our earlier reports of elevated values in HDP compared to CON [15, 58]. The 
difference in V
•
O2peak between the HDP and controls in our previous studies was 44 and 37%, 
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respectively [15, 58], whereas here it was ~25%. As V
•
O2peak was related to the Δ[K+].work-1 ratio in 
each study, this may explain the contrasting K+ regulation data. The small sample size is unlikely to 
have limited our ability to detect a difference between HDP, RTx and CON as the effect size was 
very small (effect size =0.03). At peak workrate, the lesser Δ[K+] in RTx and HDP compared to 
CON reflects their lower workrates and presumably lower muscle K+ release during the incremental 
exercise test. 
Changes in plasma [K+] may not accurately reflect changes in net muscle K+ efflux [59] due to K+ 
uptake by inactive tissues, and incomplete K+ equilibration between the muscle cell, interstitium, 
and blood [60]. For example, muscle interstitial [K+] can exceed arterial or venous [K+] by 4-8 mM 
during exercise [61, 62]. This likely explains the unchanged rise in plasma K+ in RTx and HDP 
during exercise despite their substantially reduced muscle Na+,K+-pump maximal activity and also 
the lack of correlation between plasma [K+] variables and Na+,K+-pump maximal activity (data not 
shown). Furthermore, the possibly confounding effects of hyperkalaemia at rest in HDP may have 
contributed to the apparent disconnect between plasma [K+] and Na+,K+-pump maximal activity in 
these patients.  
In conclusion, maximal exercise performance was similarly reduced in RTx and HDP with near 
normal [Hb], as was muscle maximal Na+,K+-pump activity and relative TMCSA. The depressed 
Na+,K+-pump activity is likely due to direct inhibition of Na+,K+-pumps, since muscle 
Na+,K+-pump content and isoform abundance did not differ between RTx and HDP. Finally, 
impaired exercise performance in HDP and RTx may be partially due to depressed muscle 
Na+,K+-pump activity and relative TMCSA.  
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Tables 
Table 1. Physical characteristics in renal transplant recipients, hemodialysis patients and healthy 
controls. 
 RTx HDP CON 
n  9 10 10 
Age (years) 41.3 ±  10.6 39.2 ±  8.6 39.8 ±  8.8 
Sex (F:M) 3:6 3:7 3:7 
Body mass (kg) 75.6 ± 15.7 76.8 ±  17.1 72.4 ±  16.0 
Height (m) 1.71 ±  0.13 1.75 ±  0.11 1.75 ±  0.09 
BMI (kg.m-2) 25.8 ±  3.3 25.2 ±  5.0 23.4 ±  3.7 
[ Hb]  (g.l-1) 134 ±  9 133 ±  14 145 ±  13 
Hct (%) 38.7 ±  2.5 38.3 ±  5.1 41.0 ±  3.2 
Systolic BP (mmHg) 132 ±  15 127 ±  19 124 ±  10 
Diastolic BP (mmHg) 86 ±  6 83 ±  13 81 ±  8 
Creatinine clearance (ml.min-
1) 
75.5 ±  21.6*   108.5 ±  19.2 
TMCSA (cm2) 118 ±  22 113 ±  20 131 ±  24 
Relative TMCSA (cm2.kg-1) 1.58 ±  0.23*  1.53 ±  0.22*  1.82 ±  0.16 
Values are mean ± SD; RTx, renal transplant recipients; HDP, hemodialysis patients; CON, healthy 
controls; BMI, body mass index; TMCSA, thigh muscle cross-sectional area; * less than CON, P < 
0.05.  
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Table 2. Vastus lateralis Na+,K+-pump isoform expression in RTx, HDP and CON 
 RTx HDP CON 
α1 2.3 ± 2.3 1.3 ± 1.1 2.1 ± 2.3 
α2 1.2 ± 0.8 1.7 ± 0.9 1.4 ± 0.6 
α3 3.2 ± 1.2 3.0 ± 1.5 4.8 ± 3.4 
β1 2.5 ± 1.7 1.6 ± 0.6 2.0 ± 1.0 
β2 1.5 ± 1.2 1.4 ± 0.5 1.8 ± 0.9 
β3 0.8 ± 0.8 0.7 ± 0.5 0.7 ± 0.3 
Values are mean ± SD; RTx, renal transplant recipient, n = 9; HDP, hemodialysis patient, n = 10; 
CON, healthy controls, n = 10. All values are normalized to the same human muscle standard that 
was run in all gels.  
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Table 3. Patient medications 
 RTx HDP 
Medication n Dose n Dose 
Darbepoetin (µg.fortnight-1) 1 40 6 30 ±  17 
A tenolol (mg.d-1) 2 38 ±  18 1 25 
Metoprolol (mg.d-1)   2 125 ±  106 
Ramipril (mg.d-1) 3 10 ±  0   
Irbesartan (mg.d-1) 3 53 ±  39 1 300 
Nifedipine (mg.d-1) 3 43 ±  15   
Cyclosporine (mg.d-1) 
Blood concentration (ng.ml-1) 
4 
138 ±  66 
636 ±  225 
  
Prednisolone (mg.d-1) 7 5 ±  0.5 1 2.5 
Azathioprine (mg.d-1) 3 58 ±  38   
Tacrolimus (mg.d-1) 
Blood concentration (ng.ml-1) 
5 
4 ±  1 
10.7 ±  3.8 
  
Mycophenolate mofetil (mg.d-1) 5 1338 ±  483   
Values are mean ± SD; RTx, renal transplant recipient; HDP, haemodialysis patient. 
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Table 4 Plasma acid-base and electrolyte concentrations in hemodialysis patients, renal transplant recipients and healthy controls at rest and peak 
workrate 
 RTx HDP CON 
 Rest Peak Rest Peak Rest Peak 
pH 7.41 ±  0.02 7.32 ±  0.06 7.44 ±  0.05 7.35 ±  0.03 7.42 ±  0.02 7.30 ±  0.03 
HCO3- (mmol.l-1) 24.1 ±  2.2 16.2 ±  2.9£ 27.1 ±  1.8‡ 19.2 ±  2.8 26.4 ±  2.2‡ 16.1 ±  2.8£ 
Na+  (mmol.l-1) 139 ±  3 147 ±  3 138 ±  5 144 ±  6 140 ±  2 148 ±  2 
Cl- (mmol.l-1) 108 ±  3§ 110 ±  3§ 98 ±  5 100 ±  5 105 ±  2§ 108 ±  2§ 
Ca2+  (mmol.l-1) 2.43 ±  0.16  2.57 ±  0.16    
PO4 (mmol.l-1) 0.79 ± 0.16  1.62 ±  0.29‡    
Values are mean ± SD; RTx, renal transplant recipient; HDP, haemodialysis patient; ‡ greater than RTx, P < 0.05; § greater than HDP, P < 0.05; 
£ less than HDP, P < 0.05 
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Titles and legend to figures 
Figure 1. Quadriceps peak torque during isokinetic dynamometry, expressed relative to body mass 
(A) and to thigh muscle cross-sectional area (B).  
Values are means ± SD. HDP (■), haemodialysis, n = 10; RTx (○), renal transplant, n = 9; CON 
(▲), healthy controls, n = 10. * HDP less than CON, P < 0.05; † RTx less than CON, P < 0.05. 
 
 
Figure 2. Plasma [K+] before, during, and after (A), and the rise in plasma [K+] from rest (ΔK+) 
during (B) an incremental cycle test to fatigue.  
Values are means ± SD. HDP n = 10 (■), RTx n = 9 (○), CON n = 10 (▲). # main effect exercise > 
rest (P < 0.0001); * HDP greater than CON, P < 0.05; ‡ HDP greater than RTx, P < 0.05; † RTx 
less than CON, P < 0.05. 
 
Figure 3. Muscle Na+,K+-pump activity and content measured by maximal in-vitro K+-stimulated 
3-O-methylfluorescein phosphatase activity (A) and [3H]ouabain binding site content (B).  
CON, healthy controls, n = 10, HDP, haemodialysis, n = 10, RTx, renal transplant, n = 9. Data 
expressed as mean ± SD. * less than CON, P < 0.05. 
 
Figure 4. Relationship between skeletal muscle maximal Na+,K+-pump (3-O-MFPase) activity and 
V
•
O2peak. HDP (■), haemodialysis, n = 10, RTx (○), renal transplant, n = 9, CON (▲), healthy 
controls, n = 10. Regression line is for pooled data (solid line, n =28, r = 0.45, P = 0.02, y = 4.0x + 
99.1). Dotted curves indicate 95% confidence intervals. 
 
Figure 5. Relationship between thigh muscle cross-sectional area (TMCSA) and V
•
O2peak.  
  
28 
HDP (■), haemodialysis, n = 10, RTx (○), renal transplant, n = 9, CON (▲), healthy controls, n = 
10. Regression line is for pooled data (solid line, n =28, r = 0.46, P = 0.02, y = 0.0016x + 10.8). 
Dotted curves indicate 95% confidence intervals.
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Figure 2 
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Figure 3 
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Figure 4 
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Figure 5 
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